News Nine-month-old obesity player Metsera files an IPO Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.
News Verdiva Bio raises $411m for obesity pipeline A new obesity startup – Verdiva Bio – has just decloaked with a whopping $411m to advance a once-weekly oral GLP-1 agonist.
News Novo Nordisk swells alliance with AI firm Valo Health Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.
News Novo Nordisk asks FDA not to allow GLP-1 compounding Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.
News Lilly grabs first-ever FDA nod for a sleep apnoea drug Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.
News Novo Nordisk sheds billions in value on obesity data Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.
News RFK Jr unorthodox vaccine views on show in interview Robert F Kennedy Jr's controversial views on vaccines were on display this week during an interview that touched on delays to a COVID-19 shot review.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
